Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Burzynski Research

Company price
0.0002 USD 0.00(0%)
Last update at 2026-11-19T21:00:00Z
VOLUME
60000
Market Cap
2.67M

Momentum Score

…

Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs for the treatment of various cancers. The company is involved in the research, production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name. It also offers consulting services. The company was founded in 1977 and is headquartered in Houston, Texas.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
0.02
Low
0.06
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Burzynski Research (OTC Pink: BZYR) is a small, thinly reported public company tied to the Burzynski group's development of oncology therapies. Long-term growth may depend on positive clinical results, regulatory approvals, and successful commercialization, which could support upside if milestones are achieved despite limited disclosure.

Key investment risks are high clinical and regulatory execution risk, limited financial and reporting transparency, low OTC liquidity, and potential legal or reputational uncertainty.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-
Net Debt
-0.00M
ROCE
3329.27%
Diluted EPS TTM
-0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-02-28 2024-02-29 2023-02-28 2022-02-28 2021-02-28
Type yearly yearly yearly yearly yearly
Date 2025-02-28 2024-02-29 2023-02-28 2022-02-28 2021-02-28
Income before tax -1.39M -1.34M -0.92M -0.98M -1.20M
Net income -1.39M -1.34M -0.92M -0.98M -1.20M
Selling general administrative 0.34M 0.40M 0.20M 0.22M 0.28M
Selling and marketing expenses - 0.07M - - -
Ebit - -2.67M - -0.98M -1.30M
Ebitda -1.39M -1.34M -0.92M -0.98M -1.30M
Depreciation and amortization - 1.34M - - -
Operating income -1.39M -1.34M -0.92M -0.98M -1.30M
Other operating expenses 1.39M 1.34M 0.92M 0.98M 1.30M
Interest expense - - - 0.00M 0.00M
Tax provision - 0.00M 0.00M 0.00M 0.00M
Income tax expense - -1.34M - - -0.10M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 1.39M 1.34M 0.92M 0.98M 1.30M
Total other income expense net - -0.00M - - 0.10M
Net income from continuing ops -1.39M -1.34M -0.92M -0.98M -1.20M
Net income applicable to common shares - - - -0.98M -1.20M
Breakdown 2025-02-28 2024-02-29 2023-02-28 2022-02-28 2021-02-28
Type yearly yearly yearly yearly yearly
Date 2025-02-28 2024-02-29 2023-02-28 2022-02-28 2021-02-28
Total assets 0.00M 0.00M 0.00M 0.00M 0.00M
Other current assets - 0.00M 0.00M 0.00M 0.00M
Total liab 0.04M 0.03M 0.02M 0.00M 0.05M
Total stockholder equity -0.04M -0.03M -0.01M 0.00M -0.05M
Other current liab 0.03M 0.02M 0.00M 0.00M 0.01M
Common stock 0.13M 0.13M 0.13M 0.13M 0.13M
Capital stock 0.13M 0.13M 0.13M 0.13M 0.13M
Retained earnings -129.48M -128.09M -126.75M -125.84M -124.86M
Cash 0.00M 0.00M 0.00M 0.00M 0.00M
Total current liabilities 0.04M 0.03M 0.02M 0.00M 0.05M
Net debt -0.00M -0.00M -0.00M -0.00M -0.00M
Other stockholder equity 129.30M 127.93M 126.61M 125.71M 124.68M
Total current assets 0.00M 0.00M 0.00M 0.00M 0.00M
Net tangible assets - - - 0.00M -0.05M
Accounts payable 0.02M 0.01M 0.01M 0.00M 0.03M
Non current assets total 0.00M 0.00M 0.00M 0.00M 0.00M
Breakdown 2025-02-28 2024-02-29 2023-02-28 2022-02-28 2021-02-28
Type yearly yearly yearly yearly yearly
Date 2025-02-28 2024-02-29 2023-02-28 2022-02-28 2021-02-28
Change to liabilities - - - -0.03M -0.03M
Total cash from financing activities 0.39M 0.52M 0.25M 0.33M 0.39M
Change to operating activities - - - -0.01M 0.02M
Net income -1.39M -1.34M -0.92M -0.98M -1.20M
Change in cash -0.00M 0.00M -0.00M 0.00M -0.00M
Begin period cash flow 0.00M 0.00M 0.00M 0.00M 0.00M
End period cash flow 0.00M 0.00M 0.00M 0.00M 0.00M
Total cash from operating activities -0.39M -0.52M -0.25M -0.33M -0.39M
Issuance of capital stock 0.39M 0.52M - - -
Other cashflows from financing activities 0.39M 0.52M 0.25M 0.33M 0.39M
Change to netincome - - - 0.70M 0.82M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital 0.01M 0.01M 0.01M -0.04M -0.01M
Stock based compensation 0.98M 0.80M - - -
Other non cash items 0.01M 0.80M 0.65M 0.70M 0.82M
Free cash flow -0.39M -0.52M -0.25M -0.33M -0.39M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
BZYR
Burzynski Research
-
-%
0.00 - - 7455.69 2190.81 1749.70 -5.28
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Burzynski Research

Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs for the treatment of various cancers. The company is involved in the research, production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name. It also offers consulting services. The company was founded in 1977 and is headquartered in Houston, Texas.

9432 Katy Freeway, Houston, TX, United States, 77055

713 335 5697

Name Title Year Born
Dr. Stanislaw R. Burzynski Chairman, CEO & Pres 1943
Mr. Patryk P. Goscianski Treasurer & Sec. 1978
Dr. Stanislaw R. Burzynski M.D., Ph.D. Chairman, CEO & President 1943
Mr. Patryk P. Goscianski M.B.A. CFO, Treasurer & Secretary 1978
Dr. Tomasz Janicki M.D. Vice President of Clinical Trials 1966

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…